Response to Kunos et al. and Lotersztajn and Mallat
J Clin Invest
.
2022 Jan 4;132(1):e156247.
doi: 10.1172/JCI156247.
Authors
Simeng Wang
1
,
Qingzhang Zhu
1
,
Guosheng Liang
1
2
,
Tania Franks
3
,
Magalie Boucher
3
,
Kendra K Bence
4
,
Mingjian Lu
4
,
Carlos M Castorena
1
,
Shangang Zhao
1
,
Joel K Elmquist
1
,
Philipp E Scherer
1
,
Jay D Horton
1
2
Affiliations
1
Department of Internal Medicine and.
2
Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
3
Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut, and Cambridge, Massachusetts, USA.
4
Internal Medicine Research Unit, Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts, USA.
PMID:
34981782
PMCID:
PMC8718155
DOI:
10.1172/JCI156247
No abstract available
Keywords:
Fibrosis; Insulin signaling; Metabolism; Obesity.
Publication types
Letter
Comment